Management of Persistent Mycobacterium chelonae Infection in Inguinal Lymph Nodes

Evaluation of Current Treatment Failure

• M. chelonae isolates typically show high susceptibility to clarithromycin (100%) and linezolid (90%), but lower susceptibility to doxycycline (only 25%), which may partially explain treatment failure 1, 2
• Inadequate drug penetration into lymph nodes may contribute to treatment failure 1
• Need for surgical intervention may arise due to extensive disease or failure of drug therapy alone 2, 3

Recommended Management Approach

1. Surgical Intervention

• Complete surgical excision of affected lymph nodes is the treatment of choice for localized M. chelonae lymph node disease 4, 5
• Surgery is generally indicated with extensive disease, abscess formation, or when drug therapy alone is difficult or has failed 2
• Surgical excision provides both diagnostic confirmation and therapeutic benefit 4

2. Antimicrobial Therapy Optimization

• Obtain new samples during surgical excision for culture confirmation and updated drug susceptibility testing to guide therapy 1, 2
• Revise antibiotic regimen based on susceptibility results, considering continuation of clarithromycin and addition of parenteral agents like tobramycin (100% susceptibility) or imipenem (60% susceptibility) 1, 2

Duration of Therapy

• Continue combination antibiotic therapy for at least 4-6 months after surgical excision 2, 3
• For lymph node disease without complete excision, extend treatment to 12 months of negative cultures 2
• Monitor for clinical response and adverse effects throughout treatment 1, 2

Alternative Approaches if Surgery is Not Possible

• If surgical excision is contraindicated, consider more aggressive parenteral therapy with tobramycin plus imipenem and extend duration of combination therapy to at least 12 months of negative cultures 1, 2
• Consider therapeutic drug monitoring to ensure adequate drug levels 1